Fredag 14 Mars | 14:24:53 Europe / Stockholm
2025-03-06 09:19:31

SynAct Pharma has been granted a pivotal US patent protecting the crystal form of resomelagon, a drug candidate currently in phase IIb clinical development for rheumatoid arthritis.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/03/synact-pharma-secures-key-us-patent/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se